Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
83 hedge funds and large institutions have $258M invested in Progenics Pharmaceuticals Inc in 2013 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 36 increasing their positions, 16 reducing their positions, and 12 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 16
33% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 12
15% more capital invested
Capital invested by funds: $224M → $258M (+$33.7M)
5% more funds holding
Funds holding: 79 → 83 (+4)
78% less call options, than puts
Call options by funds: $141K | Put options by funds: $638K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.5M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$1.84M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.38M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kingdon Capital Management
New York
|
-$2.58M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.49M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.42M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.32M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$1.11M |
PGNX Hedge Fund Activity: Q3 2013 in Review
83 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2013, worth a combined $258M — up 15% from $224M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PGNX positions and 12 closed out — a net gain of 4 holders — while 36 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $3.5M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $2.58M sold.
- 83 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2013, up from 79 in Q2 2013.
- Funds reported $258M of Progenics Pharmaceuticals Inc stock for Q3 2013, up 15% quarter-over-quarter.
- 16 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2013 and 12 closed out, a net change of +4 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q3 2013 was BlackRock Fund Advisors, an estimated $3.5M added.
- The largest Progenics Pharmaceuticals Inc seller in Q3 2013 was Kingdon Capital Management, an estimated $2.58M sold.
Based on aggregated 13F filings for Q3 2013.